To evaluate the clinical curative effect of Yangxinshi Pill in the treatment of chronic heart failure with meta-analysis. Methods:CNKI, VIP, CBM, WanFang, PubMed and Cochrane Library were electronically searched to collect qualified researches for evaluation. The data was analyzed by the heterogeneity test, meta-analysis and sensitivity analysis. Results:Six randomized controlled trials (RCTs) involving 559 patients with poor general quality were included. Results of meta-analyses showed that compared with the control drug group, Yangxinshi Pill could significantly improve the efficacy of 6 minutes' walk distance［WMD=49.97, 95% CI (33.22~66.71), P<0.00001］, cardiac function［OR=2.50, 95% CI (1.43~4.38), P=0.001］, traditional Chinese medicine (TCM) syndrome (chest tightness［WMD=-0.53, 95% CI (-0.76~-0.31), P<0.00001］, palpitation［WMD=-0.31, 95% CI (-0.53~-0.08), P=0.007］, hypodynamic［WMD=-0.52, 95% CI (-0.97~-0.06), P=0.03］, anhelation［WMD=-0.45, 95% CI (-0.88~-0.02), P=0.04］). There was no significant difference in left ventricular ejection fraction between two groups. Conclusion:Yangxinshi Pill is effective in the treatment of HF. However rigorously designed RCTs with large sample are still needed to support its clinical effectiveness.